Biotech
Regeneron Stops Eye Drug Study
A new eye treatment from Regeneron halts its study after a safety concern, impacting its future for patients.
Regeneron stops its study for a new eye medicine. This medicine, called an anti-CD3 antibody, aims to help people with uveitis. Uveitis is an eye disease that causes swelling and can lead to vision loss.
The study was in its early stages. Doctors watched patients closely for any problems. One patient had a serious side effect. This event made the company stop the study.
Stopping the study is a big step. It means the risks of the medicine are too high right now. The company puts patient safety first. Regeneron continues to look for other ways to help people with eye diseases.
Source: FierceBiotech
#Biotech#Healthcare#Drug Development
More from Biotech
